おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Shoreline Biosciences
company
About
Shoreline Biosciences is a biomedical company intended to establish immunotherapies for seriously ill patients.
- 1 - 10
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $140M
- Industries
- Biotechnology,Health Care,Life Science,Medical
- Founded date
- Jan 1, 2020
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Shoreline Biosciences is a biomedical company intended to establish immunotherapies for seriously ill patients. Its proprietary cell therapy technology platform is based on deep expertise in iPSC differentiation methods and genetic programming of the IL-15/CISH pathway for enhanced metabolic fitness and persistence of the engineered NK Cells to improve anti-cancer activity. The company was founded in 2020 and is headquartered in La Jolla, CA, USA.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$183M
Shoreline Biosciences has raised a total of
$183M
in funding over 2 rounds. Their latest funding was raised on
Nov 2, 2021 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 2, 2021 | Series B | $140M | 3 | — | — | Detail |
| Feb 7, 2021 | Series A | $43M | 2 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
4
Shoreline Biosciences is funded by 4 investors.
Kite Pharma
and BeiGene
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Kite Pharma
|
— | Series B |
BeiGene
|
— | Series B |
|
|
— | Series B |
Gilead Capital
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
